Publications by authors named "V Ciaravino"
Article Synopsis
- This study aimed to evaluate how well the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) measures disease impact in patients with psoriatic arthritis, focusing on score validity and change thresholds.
- Researchers analyzed data from 1252 patients undergoing treatment in two clinical trials, finding strong correlations with other patient-reported outcomes and good reliability and responsiveness of the PsAID-12 scores.
- Results indicated that the PsAID-12 is a reliable tool for assessing disease impact in patients, with established thresholds for meaningful improvement and severity levels, confirming its usefulness in clinical settings.
Introduction: Hidradenitis suppurativa (HS) has a profound negative impact on patients' health-related quality of life (HRQoL). Here we summarize the evidence on HRQoL and Patient Reported Outcomes (PROs) in patients with HS in real-world settings by conducting a systematic literature review (SLR) of observational studies.
Methods: Data sources included MEDLINE, Embase & PsycINFO between January 1, 2010 and August 29, 2021, and conference proceedings between 2019 and 2021.
Background: Hidradenitis suppurativa (HS), a chronic skin condition that causes pain and physical dysfunction, can impact significantly on quality of life. Disease-specific tools have been designed to assess the impact of HS on patients, including the HS Symptom Daily Diary (HSSDD), the HS Symptom Questionnaire (HSSQ), and the HS Quality of Life (HiSQOL©) questionnaire, which have been developed into electronic instruments (eHSSDD, eHSSQ, and eHiSQOL©).
Objectives: The objective of this study was to establish the content validity of the electronic version of the HSSDD and HSSQ, and the acceptability and usability of the HSSDD, HSSQ, and HiSQOL©, using concept elicitation and cognitive debriefing interviews.
Article Synopsis
- The study evaluates the effectiveness of the Hidradenitis Suppurativa Investigator Global Assessment (HS-IGA) score as a measurement tool in clinical trials for hidradenitis suppurativa (HS).
- Data from a phase 2 trial with adults suffering from moderate-to-severe HS was analyzed, focusing on the HS-IGA score's validity and reliability over a 12-week period.
- Results revealed that the HS-IGA score correlates strongly with other measures of HS severity, showing good reliability and being a useful potential endpoint in HS clinical trials, despite limited predictive validity with patient-reported outcomes.
Article Synopsis
- The study evaluates the long-term effectiveness of bimekizumab (BKZ) for treating moderate-to-severe plaque psoriasis over three years, particularly focusing on maintaining the results achieved at Week 16.
- Data from multiple phase III studies and an ongoing open-label extension were used, showing a significant number of patients maintaining high levels of improvement in their psoriasis symptoms throughout the three-year period.
- Overall, the results indicate that most patients who responded positively at Week 16 continued to experience substantial benefits and improvements in their quality of life due to ongoing BKZ treatment.